Galactosemia cost-effectiveness of therapy: Difference between revisions
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The cost-effectiveness of the therapy of [[galactosemia]] has primarily been studied with respect to the [[screening]] program for the [[disease]] and the benefits reaped from it. | |||
==Cost-Effectiveness of Therapy== | ==Cost-Effectiveness of Therapy== | ||
Latest revision as of 22:38, 5 July 2022
|
Galactosemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Galactosemia cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Galactosemia cost-effectiveness of therapy |
|
Risk calculators and risk factors for Galactosemia cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sujaya Chattopadhyay, M.D.[2]
Overview
The cost-effectiveness of the therapy of galactosemia has primarily been studied with respect to the screening program for the disease and the benefits reaped from it.
Cost-Effectiveness of Therapy
The screening cost of galactosemia is less than the benefits i.e. QALYs achieved through screening, thereby making its implementation cost-effective[1]. Moreover, decreasing the false-positives [2], using healthcare information systems[3] and economical diagnostic techniques, establishing a centralized laboratory [4] and combining with other screening programs [5] will help in further reducing the financial burden. The efficiency of the neonatal screening policy is also inversely related to the prevailing interest rate in the economy[6].
References
- ↑ Hatam N, Askarian M, Shirvani S, Siavashi E (2017). "Neonatal Screening: Cost-utility Analysis for Galactosemia". Iran J Public Health. 46 (1): 112–119. PMC 5401919. PMID 28451536.
- ↑ Carroll AE, Downs SM (2006). "Comprehensive cost-utility analysis of newborn screening strategies". Pediatrics. 117 (5 Pt 2): S287–95. doi:10.1542/peds.2005-2633H. PMID 16735255.
- ↑ Hsieh SH, Hsieh SL, Chien YH, Weng YC, Hsu KP, Chen CH; et al. (2010). "Newborn screening healthcare information system based on service-oriented architecture". J Med Syst. 34 (4): 519–30. doi:10.1007/s10916-009-9265-x. PMID 20703906.
- ↑ Lund AM, Hougaard DM, Simonsen H, Andresen BS, Christensen M, Dunø M; et al. (2012). "Biochemical screening of 504,049 newborns in Denmark, the Faroe Islands and Greenland--experience and development of a routine program for expanded newborn screening". Mol Genet Metab. 107 (3): 281–93. doi:10.1016/j.ymgme.2012.06.006. PMID 22795865.
- ↑ Padilla CD, Lam ST (2008). "Issues on universal screening for galactosemia". Ann Acad Med Singap. 37 (12 Suppl): 39–3. PMID 19904445.
- ↑ Camelo JS, Fernandes MI, Maciel LM, Scrideli CA, Santos JL, Camargo AS; et al. (2009). "Galactosaemia in a Brazilian population: high incidence and cost-benefit analysis". J Inherit Metab Dis. 32 Suppl 1: S141–9. doi:10.1007/s10545-009-1112-1. PMID 19418240.